These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35968786)

  • 1. Supercharged chimeric antigen receptor T cells in solid tumors.
    Pant A; Jackson CM
    J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35968786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors.
    Hong M; Talluri S; Chen YY
    Curr Opin Biotechnol; 2023 Dec; 84():103020. PubMed ID: 37976958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hurdles to breakthrough in CAR T cell therapy of solid tumors.
    Marofi F; Achmad H; Bokov D; Abdelbasset WK; Alsadoon Z; Chupradit S; Suksatan W; Shariatzadeh S; Hasanpoor Z; Yazdanifar M; Shomali N; Khiavi FM
    Stem Cell Res Ther; 2022 Apr; 13(1):140. PubMed ID: 35365241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
    Johnson A; Townsend M; O'Neill K
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CAR-T Cells in solid tumours: present and future].
    Ben Aïssa A; Niculescu MV; Migliorini D
    Rev Med Suisse; 2021 May; 17(739):985-993. PubMed ID: 34009758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.
    Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdaisat S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Gregory Sawyer W
    Acta Biomater; 2023 Dec; 172():466-479. PubMed ID: 37788737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects and challenges for use of CAR T cell therapies in solid tumors.
    Ramakrishna S; Barsan V; Mackall C
    Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
    [No Abstract]   [Full Text] [Related]  

  • 10. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bright future or blind alley? CAR-T cell therapy for solid tumors.
    Zhang K; Chen H; Li F; Huang S; Chen F; Li Y
    Front Immunol; 2023; 14():1045024. PubMed ID: 36761757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
    Tahmasebi S; Elahi R; Esmaeilzadeh A
    Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
    Miao L; Zhang Z; Ren Z; Tang F; Li Y
    Front Immunol; 2021; 12():687822. PubMed ID: 34093592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Making CAR T Cells a Solid Option for Solid Tumors.
    Schmidts A; Maus MV
    Front Immunol; 2018; 9():2593. PubMed ID: 30467505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
    Yu T; Yu SK; Xiang Y; Lu KH; Sun M
    Front Immunol; 2022; 13():936496. PubMed ID: 35903099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
    Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B
    Front Immunol; 2023; 14():1113882. PubMed ID: 37020537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy.
    Cochrane RW; Fiorentino A; Allen E; Robino RA; Quiroga J; Ferreira LMR
    Methods Mol Biol; 2024; 2748():243-265. PubMed ID: 38070118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
    Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
    Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
    Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.